These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22078241)

  • 41. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
    Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
    J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients.
    Rivero-Juárez A; Mira JA; Pérez-Camacho I; Macías J; Camacho A; Neukam K; Torre-Cisneros J; Merchante N; Pineda JA; Rivero A;
    J Antimicrob Chemother; 2011 Jun; 66(6):1351-3. PubMed ID: 21415037
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.
    Laguno M; Larrousse M; Murillas J; Blanco JL; León A; Milinkovic A; Loncá M; Martinez E; Sánchez-Tapias JM; de Lazzari E; Gatell JM; Costa J; Mallolas J
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):174-8. PubMed ID: 17106276
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Outcome of treatment with peg-interferon and ribavirin in HIV-HCV co-infected patients: "real life" single center experience].
    Veitsman E; Shahar E; Hassoun G; Lorber M; Kramskay R; Maor C; Pollack S; Baruch Y
    Harefuah; 2012 Dec; 151(12):684-7, 721, 720. PubMed ID: 23330260
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs.
    Fried R; Monnat M; Seidenberg A; Oppliger R; Schmid P; Herold M; Isler M; Broers B; Kölliker C; Schönbucher P; Frei M; Huber M
    Digestion; 2008; 78(2-3):123-30. PubMed ID: 19023207
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection.
    Farnik H; Lange CM; Sarrazin C; Kronenberger B; Zeuzem S; Herrmann E
    Clin Gastroenterol Hepatol; 2010 Oct; 8(10):884-90. PubMed ID: 20601130
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan.
    Oze T; Hiramatsu N; Yakushijin T; Mochizuki K; Imanaka K; Yamada A; Oshita M; Kaneko A; Hagiwara H; Mita E; Ito T; Nagase T; Inui Y; Hijioka T; Tamura S; Yoshihara H; Hayashi E; Imai Y; Kato M; Hosui A; Miyagi T; Yoshida Y; Ishida H; Tatsumi T; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
    J Gastroenterol; 2011 Jul; 46(7):944-52. PubMed ID: 21552988
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial.
    Berg KM; Litwin A; Li X; Heo M; Arnsten JH
    Drug Alcohol Depend; 2011 Jan; 113(2-3):192-9. PubMed ID: 20832196
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
    Watanabe S; Kobayashi Y; Kawata K; Noritake H; Chida T; Nagasawa M; Kageyama F; Kawamura K; Sasada Y; Suda T
    Intern Med; 2015; 54(3):273-9. PubMed ID: 25748735
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
    Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan.
    Hsieh MH; Yeh ML; Su TH; Liu TW; Huang CF; Huang CI; Wang SC; Huang JF; Dai CY; Kao JH; Chuang WL; Chen PJ; Liu CJ; Yu ML
    J Formos Med Assoc; 2018 Jun; 117(6):497-504. PubMed ID: 28694000
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection.
    Grebely J; Genoway K; Khara M; Duncan F; Viljoen M; Elliott D; Raffa JD; DeVlaming S; Conway B
    Int J Drug Policy; 2007 Oct; 18(5):437-43. PubMed ID: 17854734
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Peginterferon Alfa-2a plus ribavirin in Japanese patients infected with hepatitis C virus genotype 2 who failed previous interferon therapy.
    Kanda T; Nakamoto S; Nishino T; Takada N; Tsubota A; Kato K; Miyamura T; Maruoka D; Wu S; Tanaka T; Arai M; Mikami S; Fujiwara K; Imazeki F; Yokosuka O
    Int J Med Sci; 2013; 10(1):43-9. PubMed ID: 23289004
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment.
    Neukam K; Mira JA; Gilabert I; Claro E; Vázquez MJ; Cifuentes C; García-Rey S; Merchante N; Almeida C; Macías J; Pineda JA
    Eur J Clin Microbiol Infect Dis; 2012 Jun; 31(6):1225-32. PubMed ID: 21971821
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High virologic sustained response for former young intravenous drug users with chronic hepatitis C treated by pegylated interferon-alpha plus ribavirin.
    Gazdik F; Gazdikova K; Laktis K; Okruhlica L; Fejdiova K; Danis D; Pijak MR; Wsolova L; Kajaba I; Kratky A
    Bratisl Lek Listy; 2009; 110(2):77-84. PubMed ID: 19408838
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
    Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
    J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term efficacy of Peg-Interferon/Ribavirin with and without Lamivudine therapy for HBeAg-positive hepatitis B and C dual infection.
    Yeh ML; Hsieh MY; Huang CI; Huang CF; Hsieh MH; Huang JF; Dai CY; Chuang WL; Yu ML
    J Gastroenterol Hepatol; 2016 Apr; 31(4):835-41. PubMed ID: 26478984
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
    Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients.
    Rivero-Juárez A; Lopez-Cortes LF; Camacho A; Torres-Cornejo A; Pineda JA; Marquez-Solero M; Caruz A; Ruiz-Valderas R; Torre-Cisneros J; Gutierrez-Valencia A; Rivero A
    PLoS One; 2012; 7(11):e48959. PubMed ID: 23145040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.